Le Lézard
Classified in: Health
Subjects: PLW, ATY

EMED alleges RMS's HIgH-Flotm sets infringe EMED's newly issued patent in a lawsuit filed yesterday


EL DORADO HILLS, Calif., Nov. 8, 2017 /PRNewswire/ -- EMED is pleased to announce yesterday the USPTO issued US 9,808,576; a new patent that complements EMED's needle securement Intellectual Property portfolio. In continuing its business objective of vigorously defending its intellectual property, EMED filed a patent infringement on November 7, 2017 against Repro-Med Systems, Inc. (dba RMS Medical Products) alleging its "HIgH-Flo Subcutaneous Safety Needle Setstm" infringe the claims of the newly issued patent. Information about the lawsuit can be found at the Eastern District of Texas under case number 2:17-cv000728."

EMED Technologies, Inc., designs, develops and markets infusion therapy medical devices worldwide. Our FDA-cleared mechanical syringe pump infusion system for SCIg therapy includes the SCIg60 Infuser, a full line of patented Soft-Glide® needle sets and Infusets fixed-rate control sets, along with VersaRate® and VersaRate® Plus, patent-pending variable rate control sets. (PRNewsfoto/EMED Technologies Corporation)

For additional information about our patented devices, contact us at [email protected].

Global legislation is increasing requirements for devices with needles to have safety mechanisms to protect clinicians, caregivers and patients.

EMED's needle securement technology was originated in the 1990's and it has evolved to include state-of-the art patented designs applicable to Huber sets, Subcutaneous sets and other devices that require needle protection. The invention disclosed and claimed in the '576 Patent allows for the safe removal of needle infusion sets from patients and their safe disposal.  In particular, the invention solves the needle safety problem by sheathing the needle within a protective pair of folding wings during and after removal from a patient's skin. The '576 Patent is a continuation of previous EMED patents that cover an array of safety designs.

EMED pioneered the design of home infusion devices for SCIG and has since been working with clinicians to advance the standard of care in Primary Immunodeficiency by means of subcutaneous infusions at the patient's home.

"The new patent enhances EMED's needle safety Intellectual Property and is available for licensing around the world," said Paul Lambert, CEO of EMED Technologies Corporation.

EMED is fully committed to investing in the design and development of novel devices to improve the standard of care in infusion therapy. Our pipeline of infusion device platforms offers versatile options for the delivery of pharmaceuticals under specialized and proprietary delivery protocols.

To learn more about EMED visit our website at www.emedtc.com. 

Press Contact

Name:

Joseph Barbrie

Telephone:

916-932-0071

Email:

[email protected]

 

SOURCE EMED Technologies Corporation


These press releases may also interest you

at 13:05
Dr. J. Mark Tuthill Joins Gestalt Diagnostics' Strategic Advisory Board
Gestalt Diagnostics has added healthcare industry expert, Dr. J. Mark Tuthill, to serve on Gestalt's Advisory Board. He will be joining Gestalt's distinguished Advisory Board of pathologists contributing to oversight and active input of development...

at 12:45
Sogolytics Study Examines Patient Experience Gaps in Telehealth Adoption
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients. "It's critical for providers...

at 12:24
West Physics Announces Acquisition of Tricord, Inc.
West Physics Consulting, LLC ("West Physics"), the leading national provider of integrated medical and health physics services, announced today that it has completed the purchase of the medical physics service division of Tricord, Inc. ("Tricord"), a...

at 12:16
Amae Health, Innovative Treatment Provider for Severe Mental Illness, Announces Closing of Oversubscribed $15 Million Series A Funding Round
Amae Health, a trailblazer in delivering patient-centered care for people with severe mental illness, announced today the successful closing of its oversubscribed $15 million Series A funding round. The round was led by Quiet Capital and included...

at 12:08
Roivios Secures FDA Breakthrough Device Designation for JuxtaFlow® RAD, Showcases Pioneering Data at Society of Cardiovascular Anesthesiologists Annual Meeting
Roivios, a pioneering clinical-stage medical device company dedicated to transforming kidney health, is thrilled to announce it has been awarded the prestigious Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its...

at 12:06
Burrell College of Osteopathic Medicine Achieves Highest Accreditation Status from AOA Commission on Osteopathic College Accreditation
Burrell College of Osteopathic Medicine (BCOM) attained the highest level of accreditation from the American Osteopathic Association (AOA) Commission on Osteopathic College Accreditation (COCA). Burrell has been awarded the prestigious accreditation...

More news about Health...


News published on and distributed by: